Oliver Reuss

Executive Director / Investment Manager

2018 - Current

Observer, Board of Directors

2024

Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria.

Member, Board of Directors

2021

Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Currently, Brainomix utilizes its platform technology to expand into new therapeutic indications, including lung fibrosis and cancer. Brainomix is a spin-out from the University of Oxford, UK.

Member, Board of Directors

2020

Perfood develops digital therapeutics powered by proprietary technology for personalized stable-glycemic nutrition. Perfood is building a pipeline of therapeutic solutions, where its core competence of modulating the glucose metabolism and inflammatory processes add disease-specific value. Find out more on www.perfood.de

Member, Board of Directors

2019

Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. The goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Find out more on www.dopavision.com

Head of Business Model & HealthCare Innovation

2014 - 2018

Head of Prescription Medicine Strategy & Strategic Intelligence

2013 - 2014

Senior Manager PM Strategy & Portfolio Management

2012 - 2013

International Business Analysis Manager

2008 - 2011

Business Analyst

2007 - 2008

Postdoc

2006 - 2007